Last updated: September 4, 2026
The fixed-dose combination of abacavir sulfate, dolutegravir sodium, and lamivudine is marketed primarily as Triumeq by ViiV Healthcare. Triumeq remains an effective once-daily HIV-1 regimen, but its commercial position is weakening. Revenue has declined as prescribers shift toward tenofovir-based combinations, particularly Biktarvy, and toward dolutegravir/lamivudine dual therapy marketed as Dovato. Generic availability of the individual ingredients and low-cost generic versions of the triple combination are accelerating price pressure outside protected markets.
Triumeq's principal commercial asset is dolutegravir. Abacavir and lamivudine are long-established nucleoside reverse transcriptase inhibitors with broad generic competition. The product has no biosimilar exposure because it is a chemically synthesized small-molecule drug, not a biologic.
What is Triumeq and how does the combination work?
Triumeq combines three antiretroviral agents:
| Component |
Drug class |
Primary role |
| Abacavir sulfate |
Nucleoside reverse transcriptase inhibitor |
Blocks HIV reverse transcription |
| Lamivudine |
Nucleoside reverse transcriptase inhibitor |
Blocks HIV reverse transcription |
| Dolutegravir sodium |
Integrase strand transfer inhibitor |
Blocks viral DNA integration |
The U.S. product contains 600 mg of abacavir, 50 mg of dolutegravir and 300 mg of lamivudine per tablet. FDA approved Triumeq on Aug. 22, 2014, for treatment of HIV-1 infection in adults and pediatric patients weighing at least 10 kg, subject to age and dosing requirements in the label.[1]
The principal clinical limitation is abacavir. Patients must be screened for the HLA-B*5701 allele because abacavir hypersensitivity can be severe and potentially fatal. Triumeq also carries restrictions for patients with certain hepatitis B co-infections because lamivudine alone does not provide an adequate hepatitis B treatment regimen.[1]
What is the FDA regulatory status of Triumeq?
Triumeq is FDA-approved and remains commercially available in the United States. Its approval was supported by the component products Ziagen, Tivicay and Epivir, together with clinical data supporting the fixed-dose combination.
| Regulatory event |
Date |
| FDA approval of Ziagen, abacavir |
1998 |
| FDA approval of Epivir, lamivudine |
1995 |
| FDA approval of Tivicay, dolutegravir |
2013 |
| FDA approval of Triumeq |
Aug. 22, 2014 |
| Original new chemical entity exclusivity period |
Expired |
| QIDP-related regulatory exclusivity |
Expired or substantially exhausted by 2025 |
| Current commercial protection |
Primarily patent, know-how, brand and market-access protection |
Triumeq is a small-molecule product. Biosimilar substitution rules do not apply. Any competitive product generally requires an abbreviated new drug application, a 505(b)(2) application, or an equivalent national regulatory pathway outside the United States.
When does Triumeq lose exclusivity?
Triumeq's regulatory exclusivity has ended. Remaining protection depends on patents covering dolutegravir, the fixed-dose formulation and, in some jurisdictions, pediatric or formulation-specific claims.
The commercial risk is staggered rather than tied to one universal global expiry date:
| Protection layer |
Commercial status |
| Abacavir compound protection |
Expired |
| Lamivudine compound protection |
Expired |
| Dolutegravir compound protection |
Approaching expiry in major markets |
| Fixed-dose combination patents |
Potentially extend protection beyond the core dolutegravir patent |
| Pediatric exclusivity |
Time-limited and no longer a material long-term barrier |
| Regulatory data exclusivity |
Expired |
| Trademark protection for Triumeq |
Continues independently of patent expiry |
In the United States, the key timing issue is the dolutegravir patent estate. Core dolutegravir protection is generally associated with the second half of the 2020s, with pediatric extensions and formulation patents potentially affecting the precise timing of ANDA approval or commercial launch. The effective date for a generic depends on the patents listed in the FDA Orange Book, any Paragraph IV litigation and the terms of settlements between ViiV and generic applicants.[2]
A patent expiry date does not automatically establish a lawful launch date. A generic applicant may launch after invalidating or avoiding listed patents, after reaching a settlement, or after an agreed entry date.
What patents protect Triumeq?
The patent estate is centered on dolutegravir and the combination tablet rather than on abacavir or lamivudine.
Dolutegravir patents
Dolutegravir originated from the integrase inhibitor research collaboration involving Shionogi and ViiV predecessor entities. Patent families cover the chemical compound, salts, crystalline forms, pharmaceutical compositions and therapeutic use.
Relevant protection categories include:
- The dolutegravir compound and related integrase inhibitors.
- Dolutegravir sodium and other pharmaceutically acceptable salts.
- Solid-state and crystalline forms.
- Pharmaceutical compositions containing dolutegravir.
- Treatment of HIV infection using dolutegravir.
- Combinations with nucleoside reverse transcriptase inhibitors.
The compound patent is the principal U.S. market barrier. Later formulation and combination patents may provide additional leverage but are generally more vulnerable to design-around arguments than a compound patent.
Triumeq formulation and combination patents
Triumeq-related patents may cover:
- A single tablet containing abacavir, dolutegravir and lamivudine.
- Ratios and dose combinations.
- Tablet composition and excipient systems.
- Manufacturing processes that improve stability or dissolution.
- Methods of treating HIV with the three-drug combination.
Combination patents can delay an uncomplicated ANDA launch when they are listed in the Orange Book. Their practical strength depends on claim scope, prosecution history, prior art and whether a generic product uses the same formulation or process.
Orange Book status
Triumeq's Orange Book exposure should be analyzed at the product level, not by simply aggregating the patents associated with Tivicay, Ziagen and Epivir. The relevant questions are:
- Which patents are currently listed against the Triumeq NDA?
- Which listed patents expire before the core dolutegravir patents?
- Has pediatric exclusivity changed the effective date?
- Have generic applicants submitted Paragraph IV certifications?
- Has ViiV initiated litigation within the statutory 45-day period?
- Does a settlement establish an earlier authorized-generic or third-party launch?
The FDA Orange Book and the approved product labeling are the controlling sources for current listed patents and exclusivity status.[2]
What generic entry risks exist for Triumeq?
Generic risk is high outside the United States and rising in the United States.
United States
A generic Triumeq applicant must demonstrate pharmaceutical equivalence and bioequivalence. Abacavir, dolutegravir and lamivudine are all orally administered small molecules, making the product technically suitable for an ANDA pathway.
The primary barriers are:
- Listed dolutegravir patents.
- Listed fixed-dose combination patents.
- Paragraph IV litigation.
- Potential launch-at-risk exposure.
- Manufacturing requirements for a three-active-ingredient tablet.
- Commercial reluctance to enter before meaningful remaining market value exists.
The most likely U.S. launch pattern is a limited first wave of generic suppliers near the final enforceable patent date, followed by rapid price erosion. Triumeq's relatively mature patient base and competition from alternative regimens reduce the incentive for a prolonged patent challenge unless a supplier can secure substantial institutional or government volume.
Europe and other high-income markets
Patent expiry, supplementary protection certificates and national litigation create a country-by-country timeline. Some jurisdictions may permit generic or authorized-generic entry before others. European uptake is likely to be constrained by existing competition from Biktarvy, Dovato and other integrase inhibitor regimens.
Low- and middle-income countries
Generic dolutegravir-based triple therapy is already a major component of global HIV treatment programs. Voluntary licensing, procurement agreements and public-health access programs have enabled low-cost products containing dolutegravir, abacavir and lamivudine or, more commonly, dolutegravir with tenofovir and lamivudine.
The preferred global generic regimen is frequently TLD, tenofovir disoproxil fumarate/dolutegravir/lamivudine, because of cost, procurement scale and clinical positioning. That substitution limits the addressable market for generic Triumeq even where legal protection is weak.
Which companies are challenging or competing with Triumeq?
Competition comes from branded products, generic manufacturers and public-sector suppliers.
| Competitor |
Company or supplier group |
Competitive effect |
| Biktarvy |
Gilead Sciences |
Strong branded single-tablet competitor using bictegravir |
| Dovato |
ViiV Healthcare |
Cannibalizes Triumeq through two-drug therapy |
| Juluca |
ViiV Healthcare |
Targets selected virologically suppressed patients |
| Genvoya and related products |
Gilead Sciences |
Compete in integrase-based treatment |
| Generic TLD |
Multiple licensed and regional manufacturers |
Dominates many lower-income procurement markets |
| Generic abacavir/lamivudine |
Multiple manufacturers |
Reduces the value of the backbone components |
| Generic dolutegravir |
Multiple manufacturers |
Weakens the central proprietary component |
Biktarvy is the most important branded competitor in many high-income markets. It avoids abacavir-related HLA-B*5701 screening and offers a tenofovir-based backbone. Dovato competes directly within ViiV's own portfolio and has benefited from the market shift toward two-drug regimens in appropriate patients.
How has Triumeq revenue changed?
ViiV reports Triumeq sales as part of its HIV portfolio. The product reached peak commercial performance before the full impact of Biktarvy, Dovato and generic component competition. Reported annual sales have since declined materially.
| Period |
Financial trajectory |
| 2014-2016 |
Rapid adoption after launch and expansion of dolutegravir-based treatment |
| 2017-2019 |
Mature branded growth; high contribution from the United States and Europe |
| 2020-2021 |
Decline begins as Biktarvy gains share and Dovato expands |
| 2022-2023 |
Accelerated erosion from treatment switching and broader generic competition |
| 2024 onward |
Mature-product decline, with residual branded demand and public-sector volume |
ViiV's annual reports indicate a decline from approximately the mid-£1 billion range at peak to roughly the low-£1 billion range in the early 2020s, with the direction remaining negative.[3-6] Triumeq's decline has been less abrupt than a conventional immediate generic cliff because branded competition preceded broad patent expiry. The erosion reflects:
- New-patient starts favoring newer regimens.
- Existing patients switching away from abacavir.
- Dovato substituting for some three-drug therapy.
- Biktarvy's strong formulary and physician position.
- Generic availability of individual components.
- Price reductions in public procurement channels.
- Lower value of a mature product approaching patent expiry.
ViiV does not generally disclose Triumeq operating profit or product-level gross margin. The product's contribution margin is likely higher than that of low-price public-sector formulations but lower than during its launch and growth period because of rebates, contracting and price concessions.
What drives future market demand for the combination?
Triumeq retains demand in several segments:
Patients already controlled on therapy
Switching a virologically suppressed patient creates clinical and adherence considerations. Some patients remain on Triumeq because of tolerability, familiarity, efficacy and physician preference.
Patients who cannot use tenofovir
Abacavir can remain useful when renal or bone considerations make tenofovir-based treatment less attractive, although cardiovascular-risk considerations limit its use in some patients.
Fixed-dose adherence demand
The single-tablet format remains commercially relevant. However, single-tablet convenience is no longer distinctive because Biktarvy and other competing products offer the same basic administration advantage.
Resource-limited procurement
In low-income markets, Triumeq-like formulations can retain demand where abacavir is clinically preferred or where procurement systems are already configured for the product. The larger volume opportunity is generally in low-cost dolutegravir-based combinations, not the original branded product.
How strong is the Triumeq patent estate?
The estate is moderate in the near term and weakens materially after core dolutegravir protection expires.
| Patent category |
Strength assessment |
| Abacavir and lamivudine patents |
Weak or exhausted |
| Core dolutegravir compound patent |
Strongest barrier before expiry |
| Dolutegravir salt and solid-form patents |
Potentially meaningful, but susceptible to invalidity and design-around challenges |
| Triple-combination patents |
Moderate; value depends on claim breadth |
| Manufacturing patents |
Relevant where process claims are difficult to avoid |
| Method-of-use patents |
Limited ability to block all generic treatment uses |
| Trademark and brand |
Useful commercially but cannot prevent lawful generic substitution |
The estate's commercial strength is therefore front-loaded. ViiV's best defense is the dolutegravir compound patent and any enforceable listed patents with expiry dates extending beyond it. After that point, the brand faces rapid substitution because the active ingredients are well understood and the tablet is technically reproducible.
What licensing deals affect Triumeq and dolutegravir?
ViiV and the Medicines Patent Pool have supported voluntary licensing arrangements for dolutegravir in many low- and middle-income countries. These agreements have enabled generic manufacturers to supply dolutegravir-based products, including fixed-dose combinations used in HIV treatment programs.[7]
The licensing model has two effects:
- It expands access and procurement volume for dolutegravir-based therapy.
- It limits the ability to preserve Triumeq pricing in licensed territories.
The commercial impact is asymmetric. Voluntary licensing protects global public-health access and supports large-volume use of dolutegravir, but much of that volume shifts toward TLD rather than branded Triumeq.
What litigation and settlement issues affect Triumeq?
The principal litigation risk concerns Paragraph IV challenges to dolutegravir and Triumeq patents. A generic applicant that certifies a listed patent is invalid, unenforceable or not infringed can trigger a patent lawsuit. ViiV may then obtain a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and litigation developments.[8]
A settlement may provide:
- A negotiated generic entry date.
- A license for an authorized generic.
- Territory-specific launch rights.
- Restrictions on manufacturing or distribution.
- No-admission provisions.
- Commercial terms that are not publicly disclosed.
Publicly available information should be assessed through FDA Orange Book listings, federal court dockets, SEC filings and ViiV or GSK disclosures. The absence of a widely publicized settlement does not eliminate Paragraph IV risk because litigation may be confidential, unresolved or conducted against a subsidiary or contract manufacturer.
What is the outlook for Triumeq's commercial value?
Triumeq is transitioning from a growth product to a managed mature product. Its future value depends on how quickly patients switch to Biktarvy and Dovato, the timing of generic dolutegravir entry, reimbursement decisions and ViiV's ability to retain patients with clinically specific reasons to use abacavir.
The likely scenarios are:
| Scenario |
Commercial result |
| Delayed generic entry |
Gradual branded decline, with residual high-income-market revenue |
| Generic entry near core patent expiry |
Rapid price and volume erosion |
| Early successful Paragraph IV challenge |
Accelerated U.S. revenue loss |
| Continued public-sector demand |
Lower-price volume partially offsets branded decline |
| Strong Dovato substitution |
ViiV retains some franchise value but Triumeq declines faster |
| Biktarvy-led switching |
Greater loss of new starts and existing patients |
Triumeq should not be valued as a standalone long-duration growth asset. Its economic value is concentrated in remaining patent-protected years, durable patients who do not switch, and licensed or procurement channels that continue to use the combination.
Key Takeaways
- Triumeq is the principal branded product containing abacavir sulfate, dolutegravir sodium and lamivudine.
- FDA approval occurred in August 2014; regulatory exclusivity is no longer the principal barrier to competition.
- Abacavir and lamivudine are mature generic ingredients. Dolutegravir is the critical remaining proprietary asset.
- Revenue has declined from approximately the mid-£1 billion range at peak to roughly the low-£1 billion range in the early 2020s.
- Biktarvy is the leading external branded competitor, while Dovato creates internal ViiV cannibalization.
- Generic entry risk is high outside the United States and rises materially as U.S. dolutegravir patents expire.
- Biosimilar risk is irrelevant because Triumeq is a small-molecule tablet.
- Voluntary licensing has expanded global dolutegravir access but favors low-cost TLD over branded Triumeq.
- The patent estate is strongest around dolutegravir and weaker around the abacavir/lamivudine backbone.
- The likely post-exclusivity outcome is rapid price erosion, with residual demand concentrated in stable patients, selected clinical populations and public procurement markets.
FAQs
Is Triumeq being discontinued?
No. Triumeq remains an approved and marketed HIV treatment, although its sales and strategic importance are declining.
Is there a generic version of abacavir, dolutegravir and lamivudine?
Generic versions exist in several international markets and through public-health licensing channels. U.S. availability depends on Orange Book patents, FDA approval and any Paragraph IV litigation or settlement restrictions.
Is Triumeq safer than Biktarvy?
Neither product is universally safer. Triumeq requires HLA-B*5701 screening and includes abacavir, while Biktarvy uses a tenofovir-based backbone. Selection depends on patient-specific renal, bone, cardiovascular, resistance, co-infection and tolerability factors.
Does Dovato replace Triumeq?
Dovato can replace triple therapy for appropriately selected patients, but it is not interchangeable for every patient. It contains dolutegravir and lamivudine without abacavir and is used under different clinical criteria.
Will generic Triumeq reduce HIV treatment costs?
Yes. Generic competition should reduce unit prices, particularly in procurement markets. The largest savings are likely to come from generic dolutegravir-based regimens such as TLD rather than from branded Triumeq substitution alone.
References
-
U.S. Food and Drug Administration. (2024). Triumeq prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
GSK plc. (2020). Annual report 2019. GSK.
-
GSK plc. (2021). Annual report 2020. GSK.
-
GSK plc. (2023). Annual report 2022. GSK.
-
GSK plc. (2024). Annual report 2023. GSK.
-
Medicines Patent Pool. (2024). Dolutegravir licensing and access agreements. Medicines Patent Pool.
-
U.S. Food and Drug Administration. (2024). ANDA submissions and Paragraph IV patent certifications. FDA.
